The higher rate of activating PIK3CA mutations and PTEN loss in left- and right-sided colon cancers compared to rectal cancers could contribute to a lower response to anti-EGFR therapies in some colon cancers and supports the use of alternative treatments. The gene discussed is EGFR; the disease is malignant colon neoplasm.